Literature DB >> 6094134

[Antibodies against human T-cell leukemia virus type III in acquired immunodeficiency syndrome and persistent lymphadenopathy].

D Wernicke, K v d Helm, J Abb, J Eberle, G Zoulek, G Pleyl, F Deinhardt, G Riethmüller, H W Ziegler-Heitbrock, E P Rieber.   

Abstract

HTLV III and LAV, retroviruses which have recently been described in the United States and France and which seem to be different isolates of the same virus, are closely associated with the acquired immune deficiency syndrome (AIDS) and the lymphadenopathy syndrome (LAS). Sera from male homosexuals from the Federal Republic of Germany with AIDS or LAS were examined for antibodies to HTLV III (anti-HTLV III) by means of the enzyme linked immunoadsorbent assay (ELISA) and by an indirect immunofluorescence assay. 53% of the patients were anti-HTLV III positive as were 20% of symptomless homosexual men.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6094134     DOI: 10.1055/s-2008-1069439

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  5 in total

1.  Seroepidemiology of HTLV-III (LAV) in the Federal Republic of Germany.

Authors:  G Hunsmann; J Schneider; H Bayer; R Kurth; A Werner; H D Brede; V Erfle; W Mellert; H R Brodt; L Bergmann
Journal:  Klin Wochenschr       Date:  1985-03-01

2.  [AIDS and HTLV-III in West Germany: the status February 1985].

Authors:  R Hehlmann; V Erfle; G Hunsmann; R Kurth
Journal:  Klin Wochenschr       Date:  1985-05-02

3.  Professor Dr. Dr. h. c. Otto Braun-Falco.

Authors: 
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

4.  Prevalence of antibodies to human T-lymphotropic virus-III (HTLV-III) in hemophiliacs and other patients chronically substituted with blood products.

Authors:  V Erfle; R Hehlmann; W Mellert; F D Goebel; H Rasokat; E Lechler; P Hellstern; M Köhler; E Seifried; H Heimpel
Journal:  Blut       Date:  1985-10

Review 5.  Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV.

Authors:  Daniel M Himmel; Eddy Arnold
Journal:  Pharmaceuticals (Basel)       Date:  2020-06-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.